Every Form 4 that PMV Pharmaceuticals, Inc (PMVP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PMVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMVP filings page.
PMV Pharmaceuticals director Laurie Stelzer received a grant of stock options to acquire 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. All 42,000 options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting. Following this award, Stelzer holds 42,000 options directly, reflecting a compensation-related grant rather than any open-market share purchase or sale.
PMV Pharmaceuticals, Inc. director Arnold J. Levine received a grant of stock options covering 42,000 shares of Common Stock at an exercise price of $1.1900 per share. These options expire on June 4, 2036 and vest on the earlier of June 4, 2027 or the issuer's next annual meeting of stockholders, leaving him with 42,000 options following the grant.
PMV Pharmaceuticals director Carol Giltner Gallagher reported option grants and internal transfers involving 42,000-share stock options. She received a stock option for 42,000 shares of common stock at an exercise price of $1.19 per share, expiring on June 4, 2036.
According to a footnote, these options vest on the earlier of June 4, 2027 or the issuer’s next annual meeting of stockholders. The filing also shows bona fide gifts moving options covering a total of 84,000 underlying shares, including a transfer to The Gallagher Revocable Trust dated May 10, 2011, for which she serves as trustee. These are non-market, gift and grant transactions rather than open-market buys or sells.
PMV Pharmaceuticals director Kirsten Flowers received a stock option grant covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. These options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting.
PMV Pharmaceuticals director Charles M. Baum received a grant of stock options covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. They vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting. Following this award, Baum holds 42,000 stock options directly.
PMV Pharmaceuticals, Inc. Chief Financial Officer Michael Carulli reported an equity compensation grant and updated his share holdings. He received an employee stock option for 240,000 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
The option vests in 48 equal monthly installments beginning on April 5, 2026, which means the award vests gradually over four years. Following this filing, Carulli directly holds 73,848 shares of common stock, which includes 13,702 shares acquired under the company’s Employee Stock Purchase Plan on November 20, 2025.
PMV Pharmaceuticals reported that its General Counsel & COO, Robert Ticktin, received a grant of 319,270 employee stock options. These options give him the right to buy PMV Pharmaceuticals stock in the future, rather than representing shares bought on the open market.
The options were granted at an exercise price listed as $0.0000 per share in the filing and will vest over time. According to the footnote, the award vests in 48 equal monthly installments beginning on April 3, 2026, meaning the executive gains the right to exercise portions of the grant gradually over four years.
PMV Pharmaceuticals, Inc. reported that Chief Development Officer Deepika Jalota received an employee stock option grant. The award covers 303,310 options to purchase company stock and is classified as a grant or award acquisition. According to the terms, these options begin vesting on April 5, 2026, in 48 equal monthly installments, meaning the award vests gradually over four years, which is designed to align the executive’s incentives with the company’s longer-term performance.
PMV Pharmaceuticals, Inc. granted President and CEO David Henry Mack an employee stock option covering 744,960 shares of common stock. The award was reported as an acquisition of derivative securities at a stated price of 0.0000 per share. These options vest in 48 equal monthly installments beginning on April 5, 2026, providing long-term, time-based equity compensation tied to his continued service.
PMV Pharmaceuticals (PMVP) reported an insider transaction by its President and CEO (also a Director). On 10/27/2025, he exercised an employee stock option and acquired 220,643 shares of common stock at $1.37 per share.
Following the transaction, he beneficially owned 451,109 shares directly, plus indirect holdings of 165,307, 453,582, and 56,978 shares held by family trusts. The exercised option covered 220,643 shares and now has 0 remaining.
PMV Pharmaceuticals (PMVP) — Form 4 insider transaction: An affiliated holder reported a sale of 1,000,000 shares of Common Stock on 10/23/2025 at a price of $1.52 per share. Following the transaction, 4,975,291 shares were reported as beneficially owned indirectly.
According to the footnotes, the shares are held by OrbiMed Private Investments V, LP, with OrbiMed Capital GP V LLC as general partner and OrbiMed Advisors LLC as managing member. The filing notes that the reporting persons may be deemed to share voting and investment power through these relationships and include customary disclaimers of beneficial ownership beyond pecuniary interest. The reporting relationship is indicated as Director and 10% Owner.